Liling biopharmaceuticals (Suzhou) Co., Ltd – Trademark Portfolio
Entity Type: 99
Liling biopharmaceuticals (Suzhou) Co., Ltd holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 5 trademarks are registered. Notable registered marks include LEATCRT, TUREAC-T, LEATCRT-G1, LEATCRT-G2, and LEALING BIOPHARMA. The owner is based in Jiangsu.
Room 502, Building 1, Shunda Commercial
Plaza, Suzhou Industrial Park,
Jiangsu 215000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Liling biopharmaceuticals (Suzhou) Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Liling biopharmaceuticals (Suzhou) Co., Ltd have?
Liling biopharmaceuticals (Suzhou) Co., Ltd has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does Liling biopharmaceuticals (Suzhou) Co., Ltd file in?
Liling biopharmaceuticals (Suzhou) Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Liling biopharmaceuticals (Suzhou) Co., Ltd's most well-known trademarks?
Liling biopharmaceuticals (Suzhou) Co., Ltd's registered trademark portfolio includes well-known marks such as LEATCRT, TUREAC-T, LEATCRT-G1, LEATCRT-G2, and LEALING BIOPHARMA. These are among 5 currently registered trademarks in the portfolio.
What is Liling biopharmaceuticals (Suzhou) Co., Ltd's trademark registration success rate?
Liling biopharmaceuticals (Suzhou) Co., Ltd has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.